895051--3/13/2009--ENTREMED

related topics

{product, candidate, development}

{customer, product, revenue}

{product, market, service}

{debt, indebtedness, cash}

{capital, credit, financial}

{stock, price, operating}

{stock, price, share}

{personnel, key, retain}

{investment, property, distribution}

{acquisition, growth, future}

{property, intellectual, protect}

The Current Capital and Credit Market Conditions May Adversely Affect the Company s Access to Capital, Cost of Capital, and Ability to Execute its Business Plan as Scheduled We Rely Exclusively on the Royalty Payments Based upon Thalomid Sales by a Third-Party to Produce our Revenues Our Common Stock May be Delisted From The NASDAQ Capital Market, Which Could Negatively Impact the Price of Our Common Stock and Our Ability to Access the Capital Markets The Market Price of Our Common Stock May Be Highly Volatile or May Decline Regardless of Our Operating Performance Our Existing Term Loan Contains Affirmative and Negative Covenants That May Restrict our Business and Financing Activities Our Secured Lender and Preferred Stockholder Would Have Priority in Distributions Over our Common Stockholders Following a Liquidation Event Affecting the Company. As a Result, in the Event of a Liquidation Event, our Common Stockholders Would Receive Distributions Only After Priority Distributions Are Paid Development of Our Products is at an Early Stage and is Uncertain Technological Developments By Competitors May Render Our Products Obsolete We are Uncertain Whether Additional Funding Will Be Available For Our Future Capital Needs and Commitments, and If We Cannot Raise Additional Funding, or Access the Credit Markets, We May Be Unable to Complete Development of Our Product Candidates We Must Show the Safety and Efficacy of Our Product Candidates Through Clinical Trials, the Results of Which are Uncertain The Independent Clinical Investigators and Contract Research Organizations That We Rely Upon to Assist in the Conduct of Our Clinical Trials May Not Be Diligent, Careful or Timely, and May Make Mistakes, in the Conduct of Our Trials The Success of Our Business Depends Upon the Members of Our Senior Management Team, Our Scientific Staff and Our Ability to Continue to Attract and Retain Qualified Scientific, Technical and Business Personnel We May Need New Collaborative Partners to Further Develop and Commercialize Products, and if We Enter Into Such Arrangements, We May Give Up Control Over the Development and Approval Process and Decrease our Potential Revenue We Have No Current Manufacturing or Marketing Capacity and Rely on Only One Supplier For Some of Our Products Failure of Manufacturing Facilities Producing Our Product Candidates to Maintain Regulatory Approval Could Delay or Otherwise Hinder Our Ability to Market Our Product Candidates Manufacturing Our Product Candidates May Not Be Commercially Feasible We Depend on Patents and Other Proprietary Rights, Some of Which are Uncertain Our Potential Products Are Subject to Government Regulatory Requirements and an Extensive Approval Process

Full 10-K form ▸

895051--3/13/2009--ENTREMED_INC